Applied Materials Today, Год журнала: 2024, Номер 41, С. 102437 - 102437
Опубликована: Сен. 19, 2024
Язык: Английский
Journal of Hematology & Oncology, Год журнала: 2025, Номер 18(1)
Опубликована: Янв. 13, 2025
The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, signaling molecules that interact promote growth therapeutic resistance. Elucidating the intricate interactions between cells TME crucial in understanding progression challenges. A critical process induced by epithelial-mesenchymal transition (EMT), wherein epithelial acquire mesenchymal traits, which enhance their motility invasiveness progression. By targeting various components TME, novel investigational strategies aim disrupt TME's contribution EMT, thereby improving efficacy, addressing resistance, offering a nuanced approach therapy. This review scrutinizes key players emphasizing avenues therapeutically components. Moreover, article discusses implications for resistance mechanisms highlights current toward modulation along with potential caveats.
Язык: Английский
Процитировано
12
iScience, Год журнала: 2024, Номер 27(9), С. 110750 - 110750
Опубликована: Авг. 17, 2024
Innate immune cells, crucial in resisting infections and initiating adaptive immunity, play diverse significant roles tumor development. These including macrophages, granulocytes, dendritic cells (DCs), innate lymphoid innate-like T are pivotal the microenvironment (TME). components of TME, based on which various immunotherapy strategies have been explored. Immunotherapy strategies, such as novel checkpoint inhibitors, STING/CD40 agonists, macrophage-based surface backpack anchoring,
Язык: Английский
Процитировано
8
International Immunopharmacology, Год журнала: 2025, Номер 147, С. 113952 - 113952
Опубликована: Янв. 6, 2025
Regulatory T (Treg) cells, immunosuppressive CD4+ can impede anti-tumor immunity, complicating cancer treatment. Since their discovery, numerous studies have been dedicated to understand Treg cell biology, with a focus on checkpoint pathways' role in generation and function. Immune checkpoints, such as PD-1/PD-L1, CTLA-4, TIGIT, TIM-3, OX40, are pivotal controlling expansion activity the tumor microenvironment (TME), affecting ability suppress immune responses. This review examines complex relationship between these checkpoints Tregs TME, how they influence immunity. We also discuss therapeutic potential of targeting enhance including use blockade (ICB) therapies novel approaches CCR8-targeted therapies. Understanding interaction cells lead more effective immunotherapeutic strategies, combining inhibitors, improve patient outcomes
Язык: Английский
Процитировано
1
Molecules, Год журнала: 2024, Номер 29(17), С. 4280 - 4280
Опубликована: Сен. 9, 2024
In this review we explore innovative approaches in the treatment of hematologic cancers by combining various therapeutic modalities. We discuss synergistic potential inhibitors targeting different cellular pathways with immunotherapies, molecular therapies, and hormonal therapies. Examples include PI3K proteasome inhibitors, NF-κB immunotherapy checkpoint neddylation therapies tumor microenvironment. Additionally, use small molecules peptide cancer treatment. These multidimensional combinations present promising strategies for enhancing efficacy overcoming resistance mechanisms. However, further clinical research is required to validate their effectiveness safety profiles patients.
Язык: Английский
Процитировано
6
mAbs, Год журнала: 2024, Номер 17(1)
Опубликована: Дек. 22, 2024
The commercial development of antibody therapeutics is a global enterprise involving thousands biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed pipeline nearly 1,400 investigational product candidates that are undergoing evaluation clinical studies as treatments for wide variety diseases. Here, we discuss key events occurred during 2024 forecast related to the late-stage may occur 2025. In particular, report on 21 granted first approval at least one country or region 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (依達方®), antibody–drug conjugate (ADC) sacituzumab tirumotecan (佳泰萊®). We also 30 which marketing applications were review by regulatory agency, our last update December 9, ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab trastuzumab botidotin, becotatug rezetecan. Of 178 include pipeline, summarize data 18 be submitted end 2025, such bi- multispecific denecimig, sonelokimab, erfonrilimab, anbenitamab. Key trends formats bispecifics ADCs, well clinical-phase transition success rates these formats, reported.
Язык: Английский
Процитировано
4
Frontiers in Immunology, Год журнала: 2025, Номер 15
Опубликована: Янв. 8, 2025
Cholangiocarcinoma is the second most common primary liver cancer, and its global incidence has increased in recent years. Radical surgical resection systemic chemotherapy have traditionally been standard treatment options. However, complexity of cholangiocarcinoma subtypes often presents a challenge for early diagnosis. Additionally, high recurrence rates following radical resistance to late-stage limit benefits patients. Immunotherapy emerged as an effective strategy treating various types shown efficacy when combined with cholangiocarcinoma. Current immunotherapies targeting predominantly focused on T lymphocytes within tumor microenvironment, new yielded unsatisfactory results clinical trials. Therefore, it essential achieve comprehensive understanding unique microenvironment pivotal role it. In this review, we describe heterogeneous immune landscape intercellular communication summarize specific distribution lymphocytes. Finally, review potential checkpoints
Язык: Английский
Процитировано
0
Biomedicines, Год журнала: 2025, Номер 13(1), С. 216 - 216
Опубликована: Янв. 16, 2025
Background: Brain cancers represent a formidable oncological challenge characterized by their aggressive nature and resistance to conventional therapeutic interventions. The tumor microenvironment has emerged as critical determinant of progression treatment efficacy. Within this complex ecosystem, microglia macrophages play fundamental roles, forming intricate networks with peripheral immune cell populations, particularly T cells. precise mechanisms underlying microglial interactions cells contributions immunosuppression remain incompletely understood. Methods: This review comprehensively examines the cellular dialogue between in two prominent brain malignancies: primary glioblastoma secondary metastases. Results: Through comprehensive current scientific literature, we explore nuanced through which microglial-T modulate growth responses. Conclusions: Our analysis seeks unravel communication pathways that potentially underpin progression, ultimate goal illuminating novel strategies for cancer intervention.
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(2), С. 326 - 326
Опубликована: Янв. 20, 2025
Renal cell carcinoma (RCC) is a heterogeneous disease that represents the most common type of kidney cancer. The classification RCC primarily based on distinct morphological and molecular characteristics, with two broad categories: clear (ccRCC) non-clear (nccRCC). Clear predominant subtype, representing about 70–80% all cases, while subtypes collectively make up remaining 20–30%. Non-clear encompasses many histopathological variants, each unique biological clinical characteristics. Additionally, any subtype can undergo sarcomatoid dedifferentiation, which associated poor prognosis rapid progression. Recent advances in profiling have also led to identification molecularly defined further highlighting complexity this disease. While immunotherapy has shown efficacy some variants subpopulations, significant gaps remain treatment rare subtypes. This review explores outcomes across subtypes, including highlights opportunities for improving care through novel therapies, biomarker-driven approaches, inclusive trial designs.
Язык: Английский
Процитировано
0
Scandinavian Journal of Immunology, Год журнала: 2025, Номер 101(2)
Опубликована: Фев. 1, 2025
Abstract Hepatocellular carcinoma (HCC) remains one of the most challenging malignancies globally, characterized by significant heterogeneity, late‐stage diagnosis, and resistance to treatment. In recent years, advent immune‐checkpoint blockades (ICBs) targeted immune cell therapies has marked a substantial advancement in HCC However, clinical efficacy these existing is still limited, highlighting urgent need for new breakthroughs. Natural killer (NK) cells, subset innate lymphoid family, have shown unique advantages anti‐tumour response. With increasing evidence suggesting crucial role dysfunctional NK cells pathogenesis progression HCC, considerable efforts been directed toward exploring as potential therapeutic target HCC. this review, we will provide an overview normal liver immunity followed detailed discussion various cell‐based immunotherapies their applications
Язык: Английский
Процитировано
0
Journal for ImmunoTherapy of Cancer, Год журнала: 2025, Номер 13(2), С. e010728 - e010728
Опубликована: Фев. 1, 2025
Background TIGIT was identified as a target immune checkpoint for overcoming resistance to PD-(L)1-blocking antibodies. However, the clinical efficacies of antibodies were moderate in monotherapy and mixed combination with PD-(L)1 4-1BB, strong inducible costimulatory receptor, is another attractive antitumor therapeutics. This study investigated whether ABL112, an Fc-competent bispecific antibody targeting 4-1BB (TIGITx4-1BB), would enhance activity via Fcγ receptor (FcγR)-mediated macrophage activation antibody-dependent cell-mediated functions. Methods TIGIT-dependent TIGIT-blocking assessed using reporter Jurkat T cell lines expressing TIGIT, respectively. In vivo confirmed h4-1BB knock-in mice. The main subsets associated ABL112 depleting specific subtypes or FcγR-blocking effects combined pembrolizumab atezolizumab treatment two mouse models different genetic backgrounds. Statistical analysis performed one-way two-way variance (ANOVA) Dunnett’s multiple-comparison test ANOVA Fisher’s test. Results restored by blocking TIGIT–CD155 interactions, based on blockade assay. TIGITx4-1BB antibody, showed FcγRI-dependent along activation. H22 tumor high levels endogenous CD155, both parent single-domain Ab potent tumor-suppressive activity; however, only exerted long-lasting activity. induced marked decrease Treg numbers, while augmenting absolute number CD8 + cells proportion CD226 cells. expressions CXCL10, CXCL11, IFN-γ, TNF-α increased, indicating myeloid potential modification microenvironment inflammatory phenotype. not outstanding monotherapy, but also synergistic mAb compared TIGIT–PD-(L)1 treatments. Conclusions Through multiple mechanisms action, tumor-killing memory response alone anti-PD-(L)1 therapies, representing promising new cancer strategy.
Язык: Английский
Процитировано
0